Altido Bio closed a $12.5 million seed round led by ARCH Venture Partners to advance a CAR‑T therapy developed at Massachusetts General Hospital for glioblastoma. The startup, led by industry veteran Nick Leschly, is seeking a larger Series A to scale the program. Early clinical data from the investigator‑initiated program generated notable tumor shrinkage in the first three patients: two relapsed and later died, while one patient remains disease‑free more than 2.5 years post‑treatment. Altido and MGH describe the results as encouraging but preliminary; the company is framing the seed financing to support dose optimization and manufacturing scale‑up. Glioblastoma remains an area of urgent unmet need; the case illustrates both the potential and the risk of early CAR‑T work in solid tumors and why investors are selectively funding programs with compelling initial activity.